Published January 2019 | Version v1
Journal article

Survival benefit of radiotherapy for metastatic nasopharyngeal carcinoma: a retrospective analysis based on SEER database

  • 1. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan (China)
  • 2. Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan (China)
  • 3. Department of Radiation Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing (China)

Description

Objective: To analyze survival benefits of radiotherapy in patients with nasopharyngeal carcinoma (NPC) with distant metastases and analyze relevant prognostic factors. Methods: Medical records of 329 patients newly diagnosed with metastatic NPC screened from the Surveillance, Epidemiology and End Results (SEER) database (199 of 329 patients received radiotherapy) between 2010 and 2015 were retrospectively analyzed. Overall survival (OS) and disease-specific survival (DSS) were calculated by Kaplan-Meier curve. The effect of different clinicopathological factors on the clinical prognosis of metastatic NPC patients was evaluated by logrank test and Cox regression analysis. Results: The median follow-up time was 12 months. The 3- and 5- year OS rates were 27.4% and 19.7%. The median OS was 17.9 months. Univariate analysis demonstrated that patients aged < 50 years, male, undifferentiated type, stage T3 or T4, positive regional lymph node, brain and liver metastases and 1-2 metastatic sites obtained OS and DSS benefits at 3 years after radiotherapy. Univariate and multivariate Cox analyses after propensity score matching showed that radiotherapy was an independent prognostic factor for metastatic NPC (OS, P = 0.004; DSS, P = 0.014). Besides, patients aged 60-69 years (OS, P = 0.033; DSS, P = 0.045), keratinizing squamous cell carcinoma (OS, P < 0.05; DSS, P < 0.05), stage T4 (OS, P = 0.002; DSS, P = 0.024), 1-2 metastatic sites (OS, P = 0.039; DSS, P = 0.058), 3-4 metastatic sites (OS, P = 0.003; DSS, P = 0.005) and no chemotherapy (OS, P = 0.000; DSS, P = 0.000) had poor OS and DSS, whereas sex, race and degree of differentiation exerted no effect on OS and DSS. Conclusions: Radiotherapy can significantly improve the OS and DSS of patients with metastatic NPC. Prospective and randomized controlled studies are required to further explore the role of radiotherapy in the management of metastatic NPC. (authors)

Additional details

Publishing Information

Journal Title
Chinese Journal of Radiation Oncology
Journal Volume
28
Journal Issue
1
Journal Page Range
p. 5-12
ISSN
1004-4221

Optional Information

Notes
4 tabs., 21 refs.; http://dx.doi.org/10.3760/cma.j.issn.1004-4221.2019.01.002